{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:12:50Z","timestamp":1793059970563,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virs.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:13:46Z","timestamp":1780474426000},"page":"716-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The guanosine nucleotide analog bemnifosbuvir inhibits hepatitis E virus infection in cell and organoid models"],"prefix":"10.1016","volume":"41","author":[{"given":"Kuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xincheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc J.W.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6436-4573","authenticated-orcid":false,"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-6184","authenticated-orcid":false,"given":"Qiuwei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2026.05.010_bib1","doi-asserted-by":"crossref","first-page":"e01201","DOI":"10.1128\/AAC.01201-19","article-title":"Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis","volume":"63","author":"Berliba","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virs.2026.05.010_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227104","article-title":"Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus","volume":"15","author":"Good","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.virs.2026.05.010_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virs.2026.05.010_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.13237","article-title":"The global burden of hepatitis E outbreaks: a systematic review","volume":"37","author":"Hakim","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2026.05.010_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.05.010_bib6","article-title":"Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids","volume":"8","author":"Li","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virs.2026.05.010_bib7","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/liv.14468","article-title":"The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2026.05.010_bib8","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41551-025-01417-5","article-title":"Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases and enable development of multitarget therapeutics","volume":"9","author":"Liu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.virs.2026.05.010_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2022.05.006","article-title":"Chronic hepatitis E: advancing research and patient care","volume":"77","author":"Ma","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2026.05.010_bib10","series-title":"Pubchem Patent Summary for WO-2025014360-A1, Guanosine Nucleotide Analogs for Use in Preventing and\/or Treating Hepatitis E Virus Infection","author":"Pan","year":"2024"},{"key":"10.1016\/j.virs.2026.05.010_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/bdra.20682","article-title":"The Ribavirin Pregnancy Registry: findings after 5 years of enrollment, 2003-2009","volume":"88","author":"Roberts","year":"2010","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"10.1016\/j.virs.2026.05.010_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105501","article-title":"Kill or corrupt: mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2","volume":"210","author":"Shannon","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virs.2026.05.010_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-022-28113-1","article-title":"A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase","volume":"13","author":"Shannon","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virs.2026.05.010_bib14","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.00146-12","article-title":"Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination","volume":"86","author":"Shukla","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virs.2026.05.010_bib15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","article-title":"In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome","volume":"65","author":"Todt","year":"2016","journal-title":"Gut"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X2600088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X2600088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:35:31Z","timestamp":1785936931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X2600088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1995820X2600088X"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2026.05.010","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The guanosine nucleotide analog bemnifosbuvir inhibits hepatitis E virus infection in cell and organoid models","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}